SAGE Therapeutics

About:

SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.

Website: http://www.sagerx.com

Twitter/X: sagebiotech

Top Investors: OrbiMed, Biogen, ARCH Venture Partners, Foresite Capital, Third Rock Ventures

Description:

SAGE Therapeutics is dedicated to the health and well being of patients with central nervous system (CNS) disorders. Their mission is to discover, develop and deliver novel medicines for many of today's most debilitating and disabling CNS disorders by leveraging compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers.

Total Funding Amount:

$2.7B

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2010-01-01

Contact Email:

careers(AT)sagerx.com

Founders:

Douglas Covey, Steven Paul

Number of Employees:

501-1000

Last Funding Date:

2020-11-27

IPO Status:

Public

© 2025 bioDAO.ai